VERRICA PHARMACEUTICALS INC (VRCA)

US92511W1080 - Common Stock

5.65  +0.33 (+6.2%)

After market: 5.65 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (3/27/2024, 8:00:03 PM)

After market: 5.65 0 (0%)

5.65

+0.33 (+6.2%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap239.67M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VRCA Daily chart

Company Profile

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 22 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: VP-102, VP-315 and VP-103. The firm's lead product candidate, VP-102, is a drug-device combination that contains a GMP-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, a contagious and primarily pediatric viral skin disease; external genital warts (EGW), and common warts. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma and non-metastatic Merkel cell carcinoma. The firm is also developing its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot.

Company Info

VERRICA PHARMACEUTICALS INC

10 N High St Ste 200

West Chester PENNSYLVANIA 19380

P: 14844533300

CEO: Ted White

Employees: 22

Website: https://verrica.com/

VRCA News

News Image2 days ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
News Image2 days ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are...

News Image19 days ago - Kahn Swick & Foti, LLCVERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
News Imagea month ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
News Imagea month ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and...

News Imagea month ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

VRCA Twits

Here you can normally see the latest stock twits on VRCA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example